Crossmark

Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1186/s43044-025-00653-z

Published Online: 2025-06-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ahmed, Ali Ashraf Salah

Alkheder, Ahmad

Ali, Mohamed Ahmed https://orcid.org/0000-0001-8142-8073
Abdelraouf, Mohamed R.

Ashour, Toka Ahmed

Mohamed Salamah, Hazem

Mahmoud, Abdelrahman

Hakim, Diaa
License Information

Text and Data Mining valid from 2025-06-06

Version of Record valid from 2025-06-06
More Information

Article History

Received: 16 July 2024

Accepted: 15 May 2025

First Online: 6 June 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below